BLRXNasdaq

BioLineRx Ltd.

Healthcare·Oncology·Phase 3·Hevel Modi'in, Israel
Oncology

BioLineRx Ltd. (BLRX): 1 pipeline candidate · 1 upcoming catalyst · 4 clinical trials. Updated within the last hour.

5.7/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health8.9

D/E 0.75 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth3.3

1 candidate

Catalyst Momentum2.0

1 upcoming, next in ~1200d

Insider SignalN/A

N/A

A transparent, data-derived signal for BioLineRx Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$13.7M

Cash

$632K

Quarterly Burn

Runway

Revenue

Cash Runway vs Catalysts

Upcoming catalyst timeline.

Today~43 mo out
Catalyst within runway

Pipeline (1 candidate)

Upcoming Catalysts (1)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

11

Total value held

$67K

HolderSharesValue
xtx topco ltd10,941$25K
susquehanna international group, llp10,200$24K
rhumbline advisers2,353$5K
bnp paribas financial markets1,800$4K
wells fargo & company/mn1,750$4K
citigroup inc1,728$4K
morgan stanley100$230
osaic holdings, inc.26$59
rockefeller capital management l.p.12$28
danske bank a/s2$5

Showing top 10 of 11 institutional holders of BioLineRx Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

4 clinical trials·CEO: Mr. Philip A. Serlin CPA, M.B.A.

Frequently asked questions

How many drug candidates are in BioLineRx Ltd.'s pipeline?

BioLineRx Ltd. (BLRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is BioLineRx Ltd.'s lead drug candidate?

BioLineRx Ltd.'s most advanced tracked candidate is bl-8040 1.25 mg/kg + g-csf (Phase 3) for Multiple Myeloma.

What is BioLineRx Ltd.'s next catalyst?

BioLineRx Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability " — expected September 30, 2029.

What is BioLineRx Ltd.'s market capitalization?

BioLineRx Ltd.'s market capitalization is approximately $13.7M.

Who is the CEO of BioLineRx Ltd.?

Mr. Philip A. Serlin CPA, M.B.A. is the chief executive officer of BioLineRx Ltd. (BLRX).

Get the full picture on BioLineRx Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.